H ypertension is a major modifiable risk factor for cardiovascular disease (CVD) and premature mortality in the United States and worldwide. [1] [2] [3] [4] [5] Much evidence from observational studies has shown strong, positive relationships between blood pressure (BP) and risk of CVD and mortality. 6, 7 Clinical trials have documented that antihypertensive treatment reduces CVD events and all-cause mortality. A network meta-analysis of randomized clinical trials reported positive linear relationships between mean achieved systolic BP and risk of CVD and all-cause mortality; lowest risks were observed among those with achieved systolic BP of 120 to 124 mm Hg. 8 The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017 guideline) provided updated BP thresholds for defining hypertension and for the initiation of and goals of pharmacologic treatment of hypertension. 9 This guideline, which recommends lower thresholds than prior guidelines, [10] [11] [12] defines hypertension as systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg. The 2017 guideline was based on a "pragmatic interpretation of BP-related CVD risk and benefit of BP reduction in clinical trials." 9 For example, in the Systolic Blood
Pressure Intervention Trial of individuals with high CVD risk but without diabetes mellitus, compared with a standard systolic BP target of <140 mm Hg, individuals randomized to an intensive systolic BP target of <120 mm Hg had 25% lower risk of CVD events and 27% lower risk of all-cause mortality. 13 Impacts of the 2017 guideline may include increased awareness of hypertension, encouragement of lifestyle modification, and, among US adults with high risk of CVD, increased antihypertension medication initiation and intensification. 14 Prior work has assessed the potential effects of these updated criteria on the prevalence and management of hypertension.
14 Building from this prior work, here we assess temporal trends in the prevalence and burden of hypertension and proportion of controlled hypertension, as defined by the 2017 guideline, in the US adult population from 1999 through 2016.
Methods
The data and code that support the findings of this study are available from the corresponding author upon reasonable request.
Study Design and Population
Data for this study were derived from the National Health and Nutrition Examination Survey (NHANES) 1999-2016. NHANES, conducted by the National Center for Health Statistics (NCHS) of the US Centers for Disease Control and Prevention, consists of cross-sectional, nationally representative samples of the noninstitutionalized civilian US population. These samples are identified through a stratified, multistage probability sampling design. In each survey, participants completed in-home interviews and then visited a mobile examination center, where they responded to additional questionnaires and underwent a medical examination and blood sample collection. During the years 1999 to 2016, 47 133 NHANES participants, aged ≥20 years completed the in-home interview and medical examination. After excluding participants with missing systolic BP or diastolic BP (n=5490), hypertension treatment (n=161), or variables needed to define diabetes mellitus, chronic kidney disease, CVD history, or 10-year predicted CVD risk (n=3206), there were 38 276 adults with data available for analysis ( Figure 1 ). All participants provided written informed consent, and all protocols were approved by the NCHS Research Ethics Review Board (name changed from NHANES Institutional Review Board in 2003).
Data Collection
Participants completed standardized questionnaires that assessed demographics; cigarette smoking; prior diagnosis of hypertension and antihypertensive medication use; prior diagnosis of high blood cholesterol and the use of lipidlowering drugs; and history of myocardial infarction, stroke, heart failure, and diabetes mellitus. 15 During the medical examination, BP was measured after resting quietly in a seated position for 5 minutes. Three consecutive measurements were taken, with a fourth attempt potentially made if an earlier measurement was interrupted or incomplete. Mean Figure 1 . Study population.
Clinical Perspective
What Is New?
• This study reports long-term trends of prevalence and burden of hypertension and prevalence of hypertension control among US adults based on definitions from the 2017 American College of Cardiology/American Heart Association (ACC/AHA) blood pressure guideline.
• Among US adults aged ≥20, from 1999 to 2016, there was a decrease in age-adjusted prevalence of hypertension as defined by the 2017 guideline, although the absolute burden increased.
• Among adults treated for hypertension, age-adjusted control improved from 1999 to 2016, although control did not improve throughout the full period among non-Hispanic blacks, individuals aged ≥60, or those with diabetes mellitus, chronic kidney disease, or high cardiovascular disease risk.
What Are the Clinical Implications?
• Due to the increasing overall burden of hypertension, these data emphasize the importance of prevention and control of hypertension in the US general population.
systolic BP was defined as the average of 3 measurements and mean diastolic BP as the average of 3 measurements. Blood samples were collected at the mobile examination center, stored at À20°C, and sent to offsite laboratories for analyses. Not all participants had fasted before the blood draw. A participant was classified as fasting before the collection of the blood sample if the participant reported not eating or drinking anything other than water for at least 8 hours before the time of venipuncture. Body mass index was calculated as weight in kilograms divided by height in meters squared. Definitions of Hypertension, Treatment, and Control
Definitions of Diabetes
Treatment for hypertension was defined as self-reported current use of antihypertensive medication among individuals who had reported being told by a doctor or other health professional that they had high BP. Based on the 2017 guideline, hypertension was defined as mean systolic BP ≥130 mm Hg, mean diastolic BP ≥80 mm Hg, or self-reported current use of antihypertensive medication. 9 For individuals taking antihypertensive medications, control was defined as having both systolic BP <130 mm Hg and diastolic BP <80 mm Hg. 9 
Statistical Analysis
We first calculated age-standardized descriptive statistics for each 2-year cycle. Age-standardized mean systolic BP and diastolic BP within categories (sex, race/ethnicity, age, treatment for hypertension) were also calculated for each cycle. We report trends for the following race/ethnicity categories: non-Hispanic white, non-Hispanic black, and Mexican American. Though other racial/ethnic groups were not available for all cycles to allow for separate estimates for these groups, other racial/ethnic groups were included in overall analyses and other stratified analyses. Next, agestandardized prevalence of hypertension within categories of interest was calculated for each 2-year cycle. We then calculated the age-standardized proportion of controlled hypertension among individuals who were currently taking antihypertensive medication. To estimate absolute burden of hypertension (defined by 2017 guideline) among women and men over time, we calculated total population counts of women and men with hypertension, by multiplying crude agespecific hypertension prevalence with total US age-specific population estimates at the time of the respective NHANES cycle.
To estimate nationally representative estimates, we used NHANES sampling weights for all analyses. To take into account the exclusion of individuals who attended the mobile exam clinic but were missing data on either systolic or diastolic BP, hypertension treatment, or key stratification variables, the original weights were reweighted within categories of age, sex, and ethnicity, as previously described. 19 For body mass index, there were an additional 383 participants missing information in the final data set; recalibrated weights for body mass index were calculated using the same reweighting approach. Age standardization was calculated via direct standardization to the year 2010 US Census (ages 20-39, 40-59, ≥60 years). 20 Based on recommendations from the National Surveillance Definitions for Hypertension, agestandardized estimates of controlled hypertension were calculated using the subpopulation of individuals with hypertension in the 2009-2010 NHANES cycle (ages 20-39, 40-59, ≥60 years). 21 To test for temporal trends in age-standardized or agespecific measure of interest, we used weighted least squares regression models (Joinpoint software). 22 This approach takes into account the standard error of each data point when determining whether an apparent change over time is significant. As some trends for mean systolic and diastolic BP, hypertension prevalence, and proportion of controlled hypertension appeared nonlinear, we used piecewise regression to assess for changes in trends over time. 22, 23 The piecewise regression approach uses a grid-search method and permutation tests to assess whether the data better fit a linear model or piecewise model. If there was evidence that the piecewise model fit better than the linear model and there was a significant difference between the trend before and after the join point, we report the year at which the trend shifted; otherwise, we only report P for linear trend. We conducted all analyses using SAS, version 9.4 (SAS Institute, Cary, NC) or Joinpoint Regression Program software (National Cancer Institute, Bethesda, MD). All P values are 2- Table 1 . Journal of the American Heart Association sided. A 2-sided P value of 0.05 was considered statistically significant. We did not account for multiple comparisons. K.S.D. had full access to all data in the study and takes responsibility for its integrity and the data analysis.
Results
Demographic and Health Characteristics Figure 3C ). There was a linear trend of decreasing mean diastolic BP over time among ages 40 to 59 years (P-linear trend=0.002) and ≥60 years (P-linear trend=0.03).
Among individuals receiving pharmacologic antihypertensive treatment, there were not significant trends in change in mean systolic or diastolic BP, though there were suggestive patterns of decreasing BP over time ( Figures 2D and 3D ). Figure 2D ). Additionally, diastolic BP decreased over time (P-linear trend=0.04) ( Figure 3D ).
Age-Standardized and Age-Specific Prevalence of Hypertension
In the full population, age-standardized prevalence of hypertension, as defined by the 2017 guideline, decreased from 48.4% in 1999-2000 to 45.4% in 2015-2016 (Table 2 ; Plinear trend =0.02). Similar patterns of decreasing hypertension prevalence over time were observed among women, men, and non-Hispanic whites. Among individuals aged ≥60 years, there was a decrease in hypertension prevalence over time, 
Age-Standardized and Age-Specific Hypertension Control Among Treated Individuals
Among adults receiving pharmacologic treatment for hypertension, the age-standardized proportion of control tended to increase substantially over time (Table 3) 
Discussion
Based on 2017 ACC/AHA hypertension guideline criteria, among US adults, there was an improvement in agestandardized hypertension prevalence and control from 1999 through 2016. However, the absolute burden of hypertension has consistently increased. Additionally, among Piecewise regression analyses indicated that slopes were significantly different before and after joinpoint, so P value for linear trend was not reported. Please see Results section for details. § Individuals with diabetes mellitus, CKD, prior CVD (coronary heart disease, stroke, or heart failure), or among those without prior CVD, 10-year predicted atherosclerotic cardiovascular disease risk ≥10% using the Pooled Cohort Risk
Equations. 18 some groups receiving treatment, much of the improvement in hypertension control tended to occur during the early part of the period, with no significant trends in recent years. Using the 2017 guideline, long-term trends in hypertension prevalence are somewhat different than trends found when hypertension was defined on the basis of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guideline. 10 For example, based on this report, the age- Prior work comparing the 2017 guideline with earlier guidelines concluded that, among US adults, the 2017 guideline substantially increased hypertension prevalence and also the proportion of adults recommended antihypertensive treatment.
14 Our findings of long-term trends align with this recent report comparing current hypertension prevalence based on the 2017 guideline with earlier guidelines. We found a higher prevalence of hypertension based on the 2017 guideline than did analyses based on older hypertension guidelines. 24, 25 Additionally, based on the 2017 guideline, the proportion of hypertension control among those with treated hypertension is lower than that based on earlier guidelines. From 1999 to 2016, based on the 2017 definitions, the prevalence of hypertension decreased and the proportion of control among those treated increased. However, among several subgroups, there was not improvement in the proportion of hypertension control in more recent years, which is similar to overall patterns observed using earlier definitions of hypertension control or uncontrolled hypertension. 24, 25 Implementation of the 2017 guideline could potentially lead to further improvements, through improved hypertension awareness, encouragement of lifestyle modification, and, among those at high risk of CVD, the commencement or intensification of antihypertensive medication.
14 Importantly, improvements in hypertension prevalence were not consistently observed among all subgroups. The improvement in hypertension prevalence from 1999 to 2016 was observed among individuals aged ≥60 years, but not among other age groups. Age-standardized hypertension prevalence also decreased among non-Hispanic whites but not among non-Hispanic blacks or Mexican Americans. Additionally, the age-standardized prevalence of hypertension increased among those with a history of CVD or ≥10% 10-year risk of CVD.
This study has potential limitations. First, although guidelines recommend that BP measurements be taken at 2 separate visits, all NHANES BP measurements were taken at 1 visit. Therefore, the prevalence of hypertension at each time point might be overestimated, although the secular trends should be consistent. Second, because of sample size, we were unable to reliably estimate the proportion of controlled hypertension among some subgroups, such as 10-year age groups. Third, we reported the proportion of controlled hypertension only among those currently on medication. This approach was chosen, as we thought it would not be as informative to estimate hypertension control among individuals who were not, at the time, classified as hypertensive (eg, individuals with systolic BP between 130 and 140 mm Hg). Finally, our definition of hypertension control does not take into account previously diagnosed hypertension that has been controlled by lifestyle changes, rather than medication.
In summary, based on the 2017 ACC/AHA hypertension guideline, the age-standardized prevalence of hypertension decreased from 48.4% in 1999-2000 to 45.4% in 2015-2016 among US adults, although the absolute burden has consistently increased. In those receiving pharmacologic treatment for hypertension, the age-standardized proportion of hypertension control increased from 25.6% in 1999-2000 to 43.5% in 2015-2016, although there have not been consistent improvements among all subgroups throughout the full period. These data emphasize the need of continuous efforts for the prevention and control of hypertension in the US general population.
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